Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of intravitreal Bevacizumab (Avastin) versus Pegaptanib (Macugen) in neovascular age-related macular degeneration
2006-002841-34Phase 2Terminated
- Sponsor
- Dr. Gerhard Franz Kieselbach
- Start
- Jul 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of bevacizumab and pegaptanib sodium in exudative macular degeneration (2 arms), sponsored by Dr. Gerhard Franz Kieselbach. Primary endpoint: Primary visual acuity outcome. Started Jul 2006; status: terminated.
02
Drugs
bevacizumabpegaptanib sodium
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2006-002841-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002841-34.